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Summary
Objective: Prospective assessment of the efﬁcacy and tolerability of intra-articular sodium hyaluronate (SH; Ostenilmini) and triamcinolone
acetonide (TA; Volon A10) for treatment of osteoarthritis (OA) of the carpometacarpal (CMC) joint of the thumb in a 26-week, controlled,
randomized, on an intention to treat, masked-observer study.
Methods: Patients were treated with three intra-articular injections of either SH (nZ 28) or TA (nZ 28). Primary assessments were pain
according to a 100 mm visual analogue scale and extensive clinical and functional parameters such as swelling, grip power and range of
motion. The population was analysed using one- and two-sided ManneWhitney (MW) estimators.
Results: Maximum pain relief occurred at 2e3 weeks for TA and at week 26 for SH after the ﬁrst intra-articular injection. At weeks 2e3 TA was
signiﬁcantly better than SH (MW: 0.3319 and 0.3063; PZ 0.9827 and 0.9929). At week 26 a slight superiority of SH could be observed (MW:
0.53; PZ 0.3624) and non-inferiority could be proven. After 26 weeks lateral pinch power was signiﬁcantly better in the SH-group (MW:
0.6331; PZ 0.0226). In all, 88.0% of patients treated with SH and 79.1% of the TA-group described pain improvement after 26 weeks. Both
agents were well tolerated. No adverse events with causal connection to the investigational products occurred.
Conclusion: A single course of three SH injections is effective in relieving pain and improving joint function in patients with OA of the CMC joint
of the thumb. Although in comparison with triamcinolone its effects are achieved more slowly, the results indicate a superior long-lasting effect
of hyaluronan at 6 months after end of treatment period.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The age-adjusted prevalence of radiographic osteoarthritis
(OA) of the carpometacarpal (CMC) joint of the thumb has
been reported to be 7% for men and 15% for women1.
Among postmenopausal women the radiological preva-
lence is as high as 33%2. Another study showed that in
elderly white male individuals 2% of the right and 3% of the
left thumbs are affected by symptomatic OA whereas it is
found in 5% of both sides among women3. By some authors
OA of the thumb is considered to be an indicator for
a general predisposition towards OA in weight bearing
joints4. Thumb CMC OA is common but does not
necessarily lead to disability1. Therefore, it is likely to be
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Received 8 May 2005; revision accepted 26 July 2005.82underdiagnosed in clinical practice. There is a close
association between thumb CMC OA and adipositas, which
seems to be due to both the mechanical and systemic
metabolic impact of obesity5.
The symptoms are described to be such as pain,
swelling, instability, deformity and loss of motion. Common
clinical tests to assess the severity of thumb CMC OA are
pulp pinch power and pain as well as lateral pinch power
and pain. Thumb CMC OA is classiﬁed radiologically after
Kellgren 0e4 or Eaton and Glickel IeIV.
Severe disabling forms of thumb metacarpal OA are
frequently treated surgically. Among numerous procedures6
the choice is between trapeziometacarpal arthrodesis and
trapezial excision with ligament reconstruction and tendon
interposition. Both procedures had similar results with
regard to pain, function and satisfaction in a recent study7,
though some authors claim to reserve arthrodesis for
posttraumatic arthritis in young patients8.
Although there exist effective operative techniques,
conservative approaches are reported to be of high beneﬁt9.
Technical accessories, splints, nonsteroidal anti-inﬂamma-
tory drugs and extensive advice on how to accommodate
activities of daily living ﬁnd their application. One group
denied clinical beneﬁt from intra-articular steroid injection
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injection of hyaluronic acid has not been described, yet.
In synovial ﬂuid hyaluronic acid contributes to the joint
homeostasis as one of its primarily critical components11. It
was shown that in osteoarthritic joints, both the concentra-
tion and the molecular weight of intra-articular hyaluronic
acid are decreased by depolymerisation. This leads to
a reduction of viscoelasticity of the synovial ﬂuid12. Several
groups started trials on knee joints with the intention to
supplement the emptied hyaluronan stores by intra-articular
injections13,14. It was found that such injections can
augment the ﬂow of synovial ﬂuid, normalize the synthesis
and inhibit the degradation of endogenous hyaluronic acid,
and relieve joint pain15. Although some authors showed
a lack of efﬁcacy of hyaluronan injection16, a recent meta-
analysis conﬁrms its efﬁcacy and safety for the treatment in
OA of the knee17. Another meta-analysis ascribes only
small effects to intra-articular hyaluronic acid18. Preliminary
results of joints other than the knee, such as shoulder,
hand, hip, temporomandibular joint, spine, foot, and ankle,
have been promising and partially conﬁrmed results of
treatment of OA of the knee19. This study’s intention was to
determine the effects of intra-articular hyaluronic injections
into the osteoarthritic CMC joint of the thumb in comparison
with the corticosteroid triamcinolone.
Patients, materials and methods
STUDY SITE AND STUDY’S PERIOD
This randomized, prospective, active-controlled, masked-
observer study was based on an intention to treat. The
clinical trial was approved by the local ethics committee and
follows the Declaration of Helsinki principles. Patients, who
had given informed consent, were seen by the main
investigators, two orthopaedic surgeons in two centres in
the period between August 2001 and December 2003.
Patients fulﬁlling the inclusion criteria and sparing reasons
for exclusion were enrolled into the study until the number of
28 patients in each group was achieved. They were treated
either with the hyaluronic acid containing compound
(Ostenilmini) or the corticosteroid triamcinolone (Volon
A10).
Seven visits were scheduled in total. Patients were seen
weekly for the ﬁrst ﬁve appointments, administering the
intra-articular injections within meetings 2e4. No anaes-
thetic was administered prior to injection. During visit 1,
patients were checked for exclusion criteria and a wash-out
period of analgesics other than paracetamol was initiated.
Patients were assessed 3, 14 and 26 weeks after
application of the ﬁrst injection. Assessment was conducted
by two masked observers unknowing the outcome of the
patients’ randomization. The main investigators and ob-
servers had received special training in clinical assessment.
Baseline assessment was performed before injection. No
additional punctures were permitted, when entered the
study protocol.
Inclusion criteria
Patients aged between 44 and 80 years showing
symptomatic OA of the CMC joint of the thumb associated
with radiographic evidence according to the Kellgren Score
were included. For the purposes of the study, patients who
reported pain (according visual analogue scale
(VAS) R 40 mm) for at least 6 months, who were in goodgeneral condition and good compliance and who had given
their written informed consent were included. Many of these
patients presented a dissatisfying history of prior treatment
attempts, which variably included physical therapy, splints
or nutritional supplements and nonsteroidal anti-inﬂamma-
tory drugs or other oral analgesics, which had to be ceased
1 week before the ﬁrst injection. All previous treatments and
relevant concomitant diseases were recorded and checked
for exclusion criteria. Demographic data, such as initials,
gender, race, weight, height, age, and nicotine and alcohol
uptake were recorded within the baseline visit. Concomitant
medications and diseases were updated at each visit.
Additional to paracetamol no other oral analgesic was
permitted, when entered the study protocol.
Exclusion criteria
The following ﬁndings led to exclusion from the study:
History or presence of alcohol or drug abuse, psychotic
disorders, epilepsy, risk of suicide, subjects unable to
understand informed consent or having a high probability of
non-compliance, intra-articular treatment of any joint with
corticosteroids or glycosaminoglycans within 3 months or
with a sodium hyaluronate (SH)-based product within 6
months prior to the ﬁrst injection. Moreover, patients with
known allergy or other contra-indications to administered
reagents, critical skin conditions at injection side, hemarth-
rosis or joint effusion, non-osteoarthritic joint disease
(rheumatoid arthritis, inﬂammatory joint diseases, chondro-
calcinosis), immune deﬁciencies, malignant diseases, un-
controlled diabetes, use of anticoagulants or joint infection
were excluded.
Observation time and study’s endpoints
Patients were observed for 27 weeks, deﬁning the last
visit as the study’s endpoint. Study treatment was stopped
prematurely if it was the patient’s wish to terminate
participation or in case of occurrence of adverse effects of
intra-articular treatment. As the study was based on an
intention to treat, drop outs were not replaced.
SH-group
Ostenilmini (TRB Chemedica AG, Haar; 22.70V per
injection) is a sterile 1 ml pre-ﬁlled syringe containing 1%
SH destined to be directly injected into the articular cavity.
One millilitre isotonic solution contains 10.0 mg SH. Other
contents are sodium chloride, sodium monohydrogenphos-
phate, sodium dihydrogenphosphate and water for injec-
tion. The active ingredient, SH, is obtained by fermentation
of Streptococcus zooepidermicus and is highly puriﬁed. No
animal proteins are used during fermentation procedure
and hence, it has negligible allergenic potential. The
average molecular weight of the SH is 1.2 million Dalton.
Administration was conducted as recommended by the
manufacturer.
Triamcinolone acetonide (TA) group
Commercially available triamcinolone acetonide Volon
A10 (Emra-Med Arzneimittel GmbH, Trittau, Germany;
13.05V per injection) was used as treatment for the control
group. One vial Volon A10 contains 10 mg triamcinolone
acetonide (TA) in 1 ml crystal suspension. They were
administered as recommended by the manufacturer.
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Injections with the investigational products were only
administered by the two main investigators to avoid bias by
different treatment techniques. Fluoroscopy or sonography
for conﬁrmation of intra-articular injection was not applied.
Effectiveness assessments
Effectiveness assessments were carried out within every
visit by one of the two masked observers. Pain was
documented using a VAS. Other symptoms recorded were
heat, swelling and crepitations under palpation. Function
was assessed by lateral (key) pinch grip and pulp pinch grip.
Mobility was documented by radial and palmar ab-/adduction
and opposition. A screening for local or systemic side effects
was conducted at each visit and if necessary recorded.
Statistical methods
This study was based on an intention to treat, which
means that all 56 randomized patients who received at least
one injection were included into the data set. Homogeneity
analysis was performed by calculating the ManneWhitney
(MW) superiority measures, as they are robust (nonpara-
metric) and standardised measures of difference. In
addition, their two-sided 90% conﬁdence intervals (CI) were
regarded as a tool for testing equivalence (two-sided,
unidirectional) on the two-sided level aZ 0.05 (Fig. 1).
The MW estimator for the demographiceanamnestic
criteria (interpretation according to Cohen) is expressed in
values between 0 and 1. Relevant benchmarks of the effect
sizes (MW) for demographic and anamnestic criteria are the
following: 0.5: equality; 0.44 and 0.56: small differences;
0.36 and 0.64: medium-sized differences; 0.29 and 0.71:
large differences. As benchmark for statistically signiﬁcant
group differences an MW estimator of 0.36 and 0.64 will beapplied in this study. Moreover, differences were consid-
ered as statistically signiﬁcant when P! 0.05. The in-
ﬂuence of such baseline inhomogeneities upon
effectiveness results was analysed by means of supportive
stratiﬁed analyses in the sense of a sensitivity analysis.
For better interpretation of homogeneity, relevant base-
line criteria were grouped as demographic criteria (gender
and age), anamnestic criteria (morning stiffness, crunch,
pain at rest, pain on motion, pain in other joints, impairment
of function, previous therapies, Kellgren Score) and
effectiveness criteria (VAS pain, radial and palmar abduc-
tion, opposition, swelling, heat, pain on pressure, crepita-
tion, pulp pinch and lateral pinch strength (impairment), pulp
pinch and lateral pinch pain, paracetamol consumption/
week, and the global clinical impression due to investiga-
tor’s and patient’s rating).
For the conﬁrmatory analysis the one-sided Wilcoxone
ManneWhitney-test was used as a test for non-inferiority
and superiority. The medical relevance of differences
between groups was quantiﬁed using as corresponding
effect size the MW superiority measure and its one-sided
97.5% CI. The MW-measure (0.0e1.0) gives the probability
that a randomly selected patient of the test group is better
off than a randomly selected patient of the comparator
group. Benchmark values were deﬁned and applied as
mentioned above.
For the comparison purposes the MW superiority
measures were calculated as robust (nonparametric) and
standardised measures of difference, which can be applied
on all types of data, all distributions and all types of relevant
differences.
Quantitative absolute variables were described in terms
of the average and the standard deviation, percent changes
and in median values being the more robust statistic in case
a distribution is skewed. The database was not large
enough to assess whether there were differences in effects
with respect to age, gender or other subgroups.Study Number: OSTMZDSGM1
Analysis of Homogeneity: Ostenil mini vs. TA  Data Set: Intention to Treat (ITT)
Anamnestic Criteria
 Univariate Mann-Whitney Statistics and Confidence Intervals (90%-CI, two-sided)
0.29 / 0.71 = large difference; 0.36 / 0.64 = medium-sized difference; 0.44 / 0.56 = small difference; 0.5 = equality
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Fig. 1. Results of analysis of homogeneity for the anamnestic criteria with univariate MW estimators and their two-sided 90% CI. The shaded
area indicates the range of equivalence (non-relevant group differences).
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ANALYSIS OF HOMOGENEITY
Only small or medium-sized differences (MW test)
between the SH-group and the triamcinolone-group (TA)
were found with respect to gender (MW: 0.4107, lower
bound CI: 0.3137, upper bound CI: 0.5639, P-value:
0.4362) and age (MW: 0.4388, lower bound CI: 0.3256,
upper bound CI: 0.4958, P-value: 0.1771). All in all 11 male
and 45 female subjects were analysed. The median age
was 59.5 in the SH-group and 61.0 in the TA-group (Table I).
The SH-group comprised 14 cases on each side. Fifteen
left and 13 right CMC joints were treated in the TA-group.
No relevant differences were found among the anam-
nestic criteria, such as morning stiffness, crunch, pain at
rest and in motion, pain in other joints, impairment of
function, previous therapy and the radiographic severity
following the Kellgren scale (Table I). Moreover, there were
no substantial differences concerning functional effective-
ness criteria such as range of motion (radial and palmar
abduction and opposition), and arthritic symptoms such as
swelling, local hyperthermia, pain on pressure crepitations
and others (Table II). Among the functional analysis the
biggest difference was found with respect to lateral pinch
pain, with more patients in the TA-group. Nevertheless, all
functional tests showed an equal distribution between both
groups as well as parameters as paracetamol demand and
the pain intensity reported by the patient and estimated by
the physician. All in all, the two groups correspond in largest
extent.
Among the patients 11 male and 45 female subjects were
analysed. With a mean of 2.1 and a median of 2.0 the
Kellgren Score was equally distributed in both groups. The
highest number of patients was found in stadium 2 (50% of
the patients). Within the SH-group OA affected equally 14
left and right CMC joints whereas in the TA-group 15 left
and 13 right were observed.
The primary criterion of effectiveness was pain, assessed
by using the visual analogue pain grading scale according
to Huskisson (VAS: 0Z no pain, 100Zworst imaginable
pain). Analysis of VAS according to MW statistics and
appropriate CI demonstrate inferiority of SH-group (superi-
ority of TA-group) up to week 14. In week 26 a slight
superiority of SH-group could be observed and non-
inferiority could be proven statistically signiﬁcant (Fig. 2).
The development of pain scores is expressed in Table III.
For reduction of outlier’s impact, pain scores are expressed
as median rather than mean values. Expressed in percent
the long-term pain relief according to the VAS scale after
26 weeks was 56% within the SH-group and 22.6% in the
Table I
Homogeneity of demographic and anamnestic criteria, MW
variables
Criterion MW Lower
bound CI
Upper
bound CI
P-value
Gender 0.4107 0.3137 0.5639 0.4362
Age 0.4388 0.3256 0.4958 0.1771
Morning stiffness 0.4777 0.3638 0.5916 0.8077
Crunch 0.5893 0.4871 0.6915 0.2588
Pain at rest 0.5 0.432 0.568 1
Pain in motion 0.5 0.5 0.5 1
Pain in other joints 0.4107 0.3256 0.4958 0.1771
Impairment of function 0.4821 0.4328 0.5315 1
Previous therapy 0.5536 0.4478 0.6593 0.5815
Kellgren score 0.4758 0.3597 0.5918 0.7539TA-group. Triamcinolone showed a faster onset of pain
relief with a maximum at 2 and 3 weeks after the ﬁrst
injection, which was signiﬁcantly better than SH (MW:
0.3319 and 0.3063; PZ 0.9827 and 0.9929). Among
patients of the SH-group inset of pain relief was more
moderate and reached its maximum after 26 weeks. Every
reduction/increasing (regardless to what extent) of VAS was
rated as improvement/worsening. It could be observed that
the number of patients with improvement was steadily
increasing in the SH-group until the long-term observation
after 6 months. In the TA-group the number of patients with
improvement was increasing until week 3 but decreasing in
the visits after 14 and 26 weeks. An alternative pain
evaluation using an ordinal pain rating scale from 0 to 4
documented comparable results with respect to the time-
dependent effect of pain relief.
The joint function was assessed within every visit. The
focus of this study lies on the ﬁnal examination after 26
weeks (Table IV). Using the univariate MW estimators and
their one-sided 97.5% CI (a was adjusted to 0.025) the
lateral pinch (key grip) strength showed equality between
treatment groups. After 6 months of treatment moderate
superiority of the SH-group was found (MW: 0.6331, lower
bound CI: 0.5273, P-value: 0.0226). After 6 months 52.0%
of the SH-group and 42.3% of the TA-group patients
reported improvement. Lateral pinch pain showed equality
of treatment groups from weeks 1 to 14 and a slight
superiority of SH-group after 6 months (MW: 0.5731, lower
bound CI: 0.4526, P-value: 0.1966).
Assessment of the pulp pinch power showed equality of
treatment groups at week 2. For all other visits small to
medium superiority of SH-group could be observed (week
26: MW: 0.6062, lower bound CI: 0.474, P-value: 0.1045).
For pulp pinch pain equality could be observed in weeks 2,
3 and 26. In weeks 4 and 14 superiority of TA-group could
be observed (week 3: MW: 0.3618, lower bound CI: 0.2412,
P-value: 0.9934). At the end of the study improvement of
pulp pinch pain could be obtained for 72% of the patients in
the SH-group and 34.6% of the TA-group.
For radial abduction from week 1 to week 14 equality or
rather small superiority of TA-group could be observed. At
week 26 a small superiority for the SH-group could be found
(Table IV). With respect to palmar abduction for weeks 1e3
small and for weeks 14e26 medium relevant superiority of
the SH-group could be observed. For opposition small
Table II
Homogeneity of baseline effectiveness criteria, MW variables
Criterion MW Lower
bound CI
Upper
bound CI
P-value
VAS pain (mm) 0.4751 0.3509 0.5993 0.7541
Radial abduction 0.4866 0.3622 0.611 0.8674
Palmar abduction 0.4082 0.2848 0.5315 0.2399
Opposition 0.4662 0.3441 0.5883 0.6689
Swelling 0.4107 0.3154 0.5061 0.227
Heat 0.4821 0.3741 0.5902 1
Pain on pressure 0.5179 0.489 0.5467 1
Crepitation 0.5179 0.4306 0.6051 1
Pulp pinch power 0.5165 0.4531 0.58 1
Lateral pinch power 0.4107 0.3154 0.5061 0.227
Pulp pinch pain 0.4821 0.4328 0.5315 1
Lateral pinch pain 0.375 0.2864 0.4636 0.055
Paracetamol consumption
(per week)
0.4821 0.4196 0.5447 1
Pain intensity (investigator) 0.4751 0.3631 0.5871 0.8043
Pain intensity (patient) 0.4758 0.3624 0.5891 0.7792
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Fig. 2. The results of the analyses of non-inferiority for the primary effectiveness criterion VAS pain with univariate MW estimators and their
one-sided 97.5% CI (a was adjusted to 0.025).superiority of the SH-group was found throughout the study
except week 2. This superiority was relevant in weeks 14
and 26.
For swelling from weeks 1 to 14 superiority of TA-group
could be observed. After 6 months superiority of SH-group
could be observed and non-inferiority could be proven. Heat
was observed to be slightly superior in the SH-group from
week 3. For pain on pressure starting from observed
equality in week 1, superiority of TA-group was steadily
increasing till week 14. After half a year both treatment
groups ended in equality. For crepitation in all visits equality
up to small superiority for the SH-group could be observed.
Effectiveness was assessed based on a Clinical Global
Impression (CGI) rating scale completed by investigator
and patients in the last follow-up visit. Evaluation was en-
coded from 1 to 5 (very good/without complaintseworsening).
Medium/relevant superiority of SH-group could be observed
for the investigator’s judgement of CGI and small superiority
for patient’s judgement. In both cases non-inferiority of the
SH-group could be proven.
Concerning the paracetamol consumption, equality for
both treatment groups was found from weeks 1 to 3 and
Table III
Total values of VAS pain assessment (in mm from the left of
a horizontal line with a range 0e100 mm)
SH-group
(median and number)
TA-group
(median and number)
Visit 1 65.5, nZ 28 63.5, nZ 28
Visit 2 64.5, nZ 28 61.5, nZ 28
Visit 3 54.0, nZ 26 46.0, nZ 27
Visit 4 41.0, nZ 26 33.0, nZ 27
Visit 5 34.0, nZ 26 20.0, nZ 27
Visit 6 35.0, nZ 26 22.0, nZ 27
Visit 7 30.0, nZ 25 45.5, nZ 26after 6 months. In week 14 a slight superiority of
triamcinolone was observed.
Adverse events occurred in four (14.3%) subjects within
each treatment group. Causal connection to the investiga-
tional products was negated by the investigators in all
cases. Five adverse events (three in SH-group and two in
TA-group: e.g., collapse, pain in index; lumbal ischialgia
and lung carcinoma) caused the early withdrawal of
subjects from study. Incidents and near incidents which
led to death or led to a serious deterioration (life-threatening
illness or injury; permanent impairment of a body function or
permanent damage to a body structure; a condition
necessitating medical or surgical intervention to prevent
permanent impairment of a body function or permanent
damage to a body structure) in the state of health of
a patient, user or other person did not occur.
Discussion
The data illustrate the effectiveness of both hyaluronic
acid and triamcinolone in the treatment of OA of the CMC
joint of the thumb. In all, 88.0% of the patients treated with
SH and 79.1% of those treated with triamcinolone described
improvement of pain, 26 weeks after ﬁrst treatment. Both
drugs relieved clinical symptoms such as pain, lack of
function and loss of motion range. Triamcinolone showed
a faster onset of pain relief with a maximum at 2 and 3
weeks after initiation of treatment. Towards the end of the
study its positive effects were decreasing. Similar ﬁndings
were made by Caborn et al.20 in the treatment of OA of the
knee joint. Among patients of the SH-group inset of pain
relief was more moderate and reached its maximum after
26 weeks. Similar observations could be made for other
parameters such as swelling of the joint. For the lateral
pinch (key grip) strength and lateral pinch pain after 6
months of treatment moderate superiority of the SH-group
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Effectiveness criteria 26 weeks after first application (visit 7) (SH-group: nZ 25; TA-group: nZ 26)
Criterion MW Lower bound CI P-value Improvement SH (%) Improvement TA (%)
VAS pain (mm) 0.53 0.3719 0.3624 88.0 79.2
Lateral pinch power 0.6331 0.5273 0.0226 52.0 42.3
Lateral pinch pain 0.5731 0.4526 0.1966 68.0 30.8
Pulp pinch power 0.6062 0.474 0.1045 40.0 28.0
Pulp pinch pain 0.53 0.3933 0.4411 72.0 34.6
Radial abduction 0.5354 0.3807 0.3354 92.0 88.5
Palmar abduction 0.6323 0.4757 0.0532 88.0 76.9
Opposition 0.6125 0.4521 0.0896 92.0 73.1
Swelling 0.5908 0.4607 0.1467 60.0 34.6
Heat 0.5385 0.4872 0.2549 44.0 34.6
Pain on pressure 0.5054 0.3829 0.5894 28.0 26.9
Crepitation 0.4977 0.4092 0.6852 72.0 73.1
Paracetamol consumption (per week) 0.4992 0.4459 0.7647
CGI investigator 0.6246 0.4811 0.0545 88.5 80.8
CGI (patient) 0.5608 0.4131 0.2346 65.4 57.7was found. For palmar abduction, opposition and pulp pinch
power moderate superiority of SH was observed throughout
the study. The theoretical background of SH implicates that
its therapeutic success is not due to symptomatic pain
relief, but due to regeneration of viscoelasticity of the
synovial ﬂuid by reﬁlling the emptied hyaluronan stores.
Corticoid phobia by both patients and doctors should not
be underestimated. Therefore, SH offers an effective
alternative. Meenagh et al.10 stated that in their study
triamcinolone could not be proven to be beneﬁcial in
rhizarthrosis compared with placebo injection. They report
statistically signiﬁcant improvements in patient and physi-
cian global assessments at weeks 4, 12, and 24 in the
placebo group and at weeks 4 and 12 in the steroid group
indicating a strong placebo or self-limiting effect. Moreover,
none of the groups showed improvement in the VAS of pain
at 24 weeks. Contrarily our data clearly illustrate strong
positive short- and moderate long-term effects of triamcin-
olone. Expressed in percent the long-term pain relief
according to the VAS scale after 26 weeks was 22.6% in
the TA-group compared with 56% within the SH-group.
Unfortunately, it was not possible to assess patients for
longer than 6 months. A further long-term follow-up would
be of great interest. It must be admitted that the study lacks
a placebo group. Data collection was done by orthopaedists
who delivered therapy. This could be regarded as a possible
source of bias. This data cannot be compared with that of
others studies easily because of the lack of an international
assessment score for the thumb CMC joint. No conﬁrmative
diagnostics were made to assure that intra-articular
injections were appropriately placed, e.g., with ultrasound
or ﬂuoroscopy. It is likely that para-articular injection ﬁnally
affects both, TA- and SH-group equally. A risk of statistical
bias is carried by the fact that para-articular TA might
ameliorate symptoms of rhizarthrosis. In contrast SH should
be injected strictly intra-articularly to be beneﬁcial. Although
an obvious tendency towards superiority of SH in compar-
ison with triamcinolone was observed, in the majority of the
assessed parameters differences lack statistical signiﬁ-
cance.
A disadvantage of SH treatment is the necessity of three
intra-articular injections carrying the risk of iatrogenic
infection. Moreover, its effect latency can cause dissatis-
faction among patients. Treatment with three injections of
SH (68V) is pricier than triamcinolone (39V).
Until today, there are no data suggesting what the exact
dosing regimen of SH injections should be. It is believedthat better results could be achieved by administering an
optimal regimen.
With respect to the long-term results, SH seems to be the
better alternative in treatment of the OA of the thumb CMC
joint. In comparison with triamcinolone it shows slide to
moderate superiority in almost all the assessed clinical
parameters after 6 months with signiﬁcant superiority in
lateral pinch pain.
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